US EPA ARCHIVE DOCUMENT

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

RETURN TO NLAP FILE
H. Raltech Wi - FY 84

FILE COPY

OFFICE OF
PESTICIDES AND TOXIC SUBSTANCES

September 25, 1984

MEMORANDUM

SUBJECT: Review of Partial For Cause Laboratory Audit
Hazleton (Raltech), Madison, Wi. May 1984

FROM: Alvaro A. Yamhure, Acting Manager
National Laboratory Audit Program
Benefits and Use Division (TS-768-C)

TO: Dexter S. Goldman, Head
Laboratory Data Integrity Program
Compliance Monitoring Staff (EN-342)

The attached memorandum is a signoff by RD and HED Toxicology Branch for the Metolachlor (rat) study by Hazleton (Raltech), Madison, Wi. This special request for-cause partial data audit was conducted May 8-10, 1984.

Richard Mountfort, PM 23-RD, states no further action is needed on this audit. With reference to the Agency's request to Ciba-Geigy for a rereading of the slides of liver tissue, RD advises that Toxicology Branch will review the rereading when that report is submitted.

Attachment:
Memo 09/20/84 from HED
Note 09/21/84 from RD

TS-768-C:BBStarry:557-5781:09/24/84

ROUTING AND TRANSMITTAL SLIP

Date 9/21/84

TO: (Name, office symbol, room number, building, Agency/Post)	Initials	Date
1. John McCann		
2.		
3.		
4.		
5.		

Rec'd SEP 21 1984 NLAP BBS

	Action		File		Note and Return
	Approval		For Clearance		Per Conversation
	As Requested		For Correction		Prepare Reply
	Circulate		For Your Information		See Me
	Comment		Investigate		Signature
	Coordination		Justify		

REMARKS

metolachlor rat study: Lab audit
Copy of Toxicology Br., HED review of audit report attached. No further action needed on audit. TB will review independent reading of liver slides when that report is submitted.

DO NOT use this form as a **RECORD** of approvals, concurrences, disposals, clearances, and similar actions.

FROM: (Name, org. symbol, Agency/Post)	Room No.—Bldg.
Dicka Mountfort	Phone No. 557-183

5041-102

OPTIONAL FORM 41 (Rev. 7-76)
Prescribed by GSA
FPMR (41 CFR) 101-11.206

* GPO : 1981 O - 341-525 (120)

SEP 20 1984

MEMORANDUM

SUBJECT: Review of Laboratory Audit Report for Metolachlor Chronic Rat Study, TOX Chem.#188DD

TO: R. Mountfort, PM#23
Registration Division (TS-767C)

FROM: Gary J. Burin, Toxicologist
Section V, Toxicology Branch
Hazard Evaluation Division (TS-769C)

THRU: William L. Burnam, Chief
Toxicology Branch
Hazard Evaluation Division (TS-769C)

Recommendations: TOX Branch concludes that issues originally triggering the need for a laboratory audit have now been adequately resolved. A rereading of the slides of liver tissue was requested by the Agency in the memo of 2/16/84 from R. Mountfort to Gene Holt of Ciba-Geigy per the suggestion of D.Goldman (Head, Data Integrity Program) in his memo of 1/26/84. When this rereading is complete, it is recommended that a revised estimate of risk be prepared based on the incidence of liver tumors. The audit found no study deficiencies which would preclude this study from being classified as Core Minimum data.
NOTE: The laboratory audit report submitted to TOX Branch was not signed by a representitive of the National Laboratory Audit Program (NLAP). Item 2 in the "Procedures" section of SOP 3050.4 requires that lab audit reports be reviewed by NLAP. This audit therefore apparently did not follow the procedures required by SOP 3050.4. However, NLAP accepts the conclusions of this audit (personal conversation with A. Gross, 9/14/84).

Background: In my memo of 12/14/83, I recommended a laboratory audit be conducted based on conflicting reports of the incidence of liver tumors in the preliminary and final reports for this study. That audit was carried out during May 8-10, 1984 by Ronald R. Ruff, FDA Investigator and M. Adrian Gross, representative of the Office of Pesticide Programs, National Laboratory Audit Program. The lab audit has been reviewed in the context of Standard Operating Procedure 3050.4 and a brief discussion of the findings of that report is presented below.

Discussion: The laboratory audit found that the liver pathology of this study was expedited at the request of the sponsor. The examining pathologist, Dr. Terry A. Jackson, stated to the audit team that initial pathology (reported in the preliminary report) was "gone through hurriedly .... without looking at the pathology sheets." Only routine liver slides were initially examined and tumors that were associated with gross lesions were not included in initial compilation. The examining pathologist also indicated that the initial report may have "overinterpreted" findings and that the diagnoses changed after "literature research and discussion with other pathologists, primarily Dr. Dick Voelker, Head of Pathology, Hazleton Laboratories, Vienna, Virginia...".

The audit did not find any evidence of correspondence with the sponsor on these changes. A selected rereading of slides by Dr. Gross during the course of the audit found that rediagnoses made by the original pathologist were not "unreasonable" (quote from Dr. Gross on p.5 of the lab audit report).

Possible deviations from Good Laboratory Practices regulations were noted but they were of a minor nature which does not effect the validity of the study results. The most significant of the deviations was the lack of retention of raw data (handwritten notes, computer printouts, etc.) for the diagnoses that were originally conducted and entered into the computer. The FDA investigator commented that "FDA surely wouldn't object to this type of raw data retention ... but probably would not require it, with (a) final report signed and dated by the pathologist available." It is noted by this reviewer that the examination of slides during the course of this audit further supported the propriety of the changes in diagnoses.